Target Name: GUCY1A1
NCBI ID: G2982
Review Report on GUCY1A1 Target / Biomarker Content of Review Report on GUCY1A1 Target / Biomarker
GUCY1A1
Other Name(s): GC-SA3 | soluble guanylate cyclase large subunit | GCS-alpha-3 | GCYA1_HUMAN | GUC1A3 | guanylate cyclase 1 soluble subunit alpha 1 | GUCY1A3 | GCS-alpha-1 | Guanylate cyclase soluble subunit alpha-3 isoform A | Guanylate cyclase soluble subunit alpha-1 | Soluble guanylate cyclase large subunit | GUCA3 | GUCY1A3 variant 4 | guanylate cyclase 1, soluble, alpha 3 | Guanylate cyclase soluble subunit alpha-3 | GC-S-alpha-1 | Guanylate cyclase 1, soluble, alpha 3 | GUCSA3 | Guanylate cyclase 1, soluble, alpha 3, transcript variant 4 | MYMY6 | Soluble guanylate cyclase alpha 3

GUCY1A1: A Potential Drug Target Or Biomarker for Various Diseases

GUCY1A1, also known as GC-SA3, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The gene is located on chromosome 10q35 and has been shown to be involved in the development and progression of these diseases.

GUCY1A1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells in the body. It is a part of a larger non-coding RNA cluster known as the GUCY1A1 cluster, which is located on the same chromosome 10q35 region as GUCY1A1. The GUCY1A1 cluster is thought to play a role in the regulation of gene expression and cell development.

One of the most promising aspects of GUCY1A1 is its potential as a drug target. GUCY1A1 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. It is also known to be involved in the regulation of cell proliferation and survival, which could make it an attractive target for drugs that are designed to inhibit these processes.

In cancer, GUCY1A1 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancers. Studies have shown that inhibiting GUCY1A1 using small molecules or antibodies can inhibit the growth and survival of cancer cells. This suggests that GUCY1A1 may be an effective target for cancer treatments.

In neurodegenerative disorders, GUCY1A1 has been shown to be involved in the development and progression of diseases such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of characteristic symptoms. Studies have shown that inhibiting GUCY1A1 using small molecules or antibodies can improve cognitive function and reduce the symptoms of neurodegenerative disorders.

In autoimmune diseases, GUCY1A1 has been shown to be involved in the development and progression of conditions such as rheumatoid arthritis and lupus. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. Studies have shown that inhibiting GUCY1A1 using small molecules or antibodies can reduce inflammation and improve the symptoms of autoimmune diseases.

GUCY1A1 is also a potential biomarker for various diseases. Its expression has been shown to be associated with the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that GUCY1A1 may be a useful biomarker for these conditions.

In conclusion, GUCY1A1 is a gene that has been identified as a potential drug target or biomarker for various diseases. Its expression is involved in the development and progression of cancer, neurodegenerative disorders, and autoimmune diseases. In addition, GUCY1A1 is also a potential biomarker for these conditions. Further research is needed to fully understand the role of GUCY1A1 in disease and to develop effective treatments.

Protein Name: Guanylate Cyclase 1 Soluble Subunit Alpha 1

The "GUCY1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GUCY1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GUCY1A2 | GUCY1B1 | GUCY1B2 | GUCY2C | GUCY2D | GUCY2EP | GUCY2F | GUCY2GP | GUF1 | GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P